Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.0K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.0K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Spinal Cord Anatomy for Visually Impaired Students: The Development of 3D-Printed Educational Models.

Journal of undergraduate neuroscience education : JUNE : a publication of FUN, Faculty for Undergraduate Neuroscience·2026
Same author

Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy.

American heart journal·2025
Same author

Cardiac Progenitor Cells in HLHS: Feasibility Now, Efficacy Next?

JACC. Heart failure·2025
Same author

Survival, clinical, and genetic findings in paediatric cardiomyopathy: a five-year prospective study from Brazil.

Cardiology in the young·2025
Same author

Cell therapy for heart failure -recent progress and future directions.

Progress in cardiovascular diseases·2025
Same author

A New Method Using Deep Learning to Predict the Response to Cardiac Resynchronization Therapy.

Journal of imaging informatics in medicine·2025

相关实验视频

Updated: May 4, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.1K

对于严重的慢性缺血性心力衰竭,进行跨内心,自主骨髓细胞移植.

Emerson C Perin1, Hans F R Dohmann, Radovan Borojevic

  • 1Texas Heart Institute at St Luke's Episcopal Hospital, Houston, Tex, USA. eperin@crescentb.net

Circulation
|April 23, 2003
PubMed
概括

骨髓干细胞注射对于严重心力衰竭患者是安全的. 这种治疗改善了心脏功能和血液流动,为缺血性心脏病提供了潜在的新疗法.

更多相关视频

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

9.9K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.2K

相关实验视频

Last Updated: May 4, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.1K
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

9.9K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.2K

科学领域:

  • 心血管医学 心血管医学
  • 再生医学是一种再生医学.
  • 干细胞疗法是一种干细胞疗法.

背景情况:

  • 末期缺血性心脏病在治疗中带来了重大挑战.
  • 新血管化,改善 perfusion 和心肌收缩性对于管理心力衰竭至关重要.

研究的目的:

  • 评估自主单核骨髓细胞的跨内脏注射的安全性和有效性.
  • 评估在患有严重缺血性心脏病的患者中促进新血管化和改善心脏功能的潜力.

主要方法:

  • 这是一项前性,非随机的开放性研究,涉及21名患者 (14名治疗,7名对照).
  • 骨髓单核细胞被注射到通过电机绘图 (NOGA导管) 识别的可活性心肌中.
  • 评估包括临床评估,运动压力测试,心声学,SPECT输液扫描和霍尔特监测.

主要成果:

  • 在基线人口统计或运动变量之间没有显著差异.
  • 2个月后,SPECT分析显示可逆性缺陷减少,左心室功能总体改善 (P=0.02).
  • 在4个月后,接受治疗的患者表现出改善的射出分数 (20%至29%,P=0.003) 和降低的末缩体积 (P=0.03),注射部分有显著的机械改善 (P<0.0005).

结论:

  • 骨髓衍生干细胞的心内注射在患有严重心力衰竭的人群中相对安全.
  • 该程序显示了改善心肌动脉血流和增强区域和全球左心室功能的潜力.